Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study

WS Lim, MM Van der Eerden, R Laing, WG Boersma… - Thorax, 2003 - thorax.bmj.com
Background: In the assessment of severity in community acquired pneumonia (CAP), the
modified British Thoracic Society (mBTS) rule identifies patients with severe pneumonia but not …

[HTML][HTML] Duration and key determinants of infectious virus shedding in hospitalized patients with coronavirus disease-2019 (COVID-19)

…, JJ Cornelissen, RAS Hoek, MM van der Eerden… - Nature …, 2021 - nature.com
Key questions in COVID-19 are the duration and determinants of infectious virus shedding.
Here, we report that infectious virus shedding is detected by virus cultures in 23 of the 129 …

Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double-blind …

…, JGJV Aerts, MM van der Eerden - The Lancet …, 2014 - thelancet.com
Background Macrolide resistance is an increasing problem; there is therefore debate about
when to implement maintenance treatment with macrolides in patients with chronic …

[HTML][HTML] Recommendations for antibacterial therapy in adults with COVID-19–an evidence based guideline

…, TJ Verheij, MM van der Eerden… - Clinical microbiology …, 2021 - Elsevier
Scope The Dutch Working Party on Antibiotic Policy constituted a multidisciplinary expert
committee to provide evidence-based recommendation for the use of antibacterial therapy in …

Convalescent plasma for COVID-19. A randomized clinical trial

…, J Miedema, M van der Eerden… - MEDRxiv, 2020 - medrxiv.org
Structured abstract for full paper Background After recovery from COVID-19, most patients
have anti-SARS-CoV-2 neutralizing antibodies. Their convalescent plasma could be an …

Shedding of infectious virus in hospitalized patients with coronavirus disease-2019 (COVID-19): duration and key determinants

…, JJ Cornelissen, RAS Hoek, MM van der Eerden… - MedRxiv, 2020 - medrxiv.org
Background Long-term shedding of viral RNA in COVID-19 prevents timely discharge from
the hospital or de-escalation of infection prevention and control practices. Key questions are …

[HTML][HTML] Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection

…, J Miedema, M van der Eerden… - Nature …, 2021 - nature.com
In a randomized clinical trial of 86 hospitalized COVID-19 patients comparing standard care
to treatment with 300mL convalescent plasma containing high titers of neutralizing SARS-…

The EMBARC European Bronchiectasis Registry: protocol for an international observational study

…, K Dimakou, I Clifton, M Van Der Eerden… - ERJ open …, 2016 - Eur Respiratory Soc
Bronchiectasis is one of the most neglected diseases in respiratory medicine. There are no
approved therapies and few large-scale, representative epidemiological studies. The …

Laboratory diagnosis of pneumonia in the molecular age

…, C Cilloniz, J Vila, M Van der Eerden - European …, 2016 - Eur Respiratory Soc
Pneumonia remains a worldwide health problem with a high rate of morbidity and mortality.
Identification of microbial pathogens which cause pneumonia is an important area for …

Community-acquired pneumonia related to intracellular pathogens

…, A Torres, M Niederman, M van der Eerden… - Intensive care …, 2016 - Springer
Community-acquired pneumonia (CAP) is associated with high rates of morbidity and mortality
worldwide; the annual incidence of CAP among adults in Europe has ranged from 1.5 to …